RESEARCH PAPER
Interactions of levetiracetam with ethosuximide in the mouse 6 Hz psychomotor seizure model – a type II isobolographic analysis
 
More details
Hide details
1
Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland; Department of Pathophysiology, Medical University, Lublin, Poland
2
Department of Pathophysiology, Medical University, Lublin, Poland
3
Department of Public Health, Institute of Rural Health, Lublin, Poland
CORRESPONDING AUTHOR
Jarogniew J. Łuszczki   

Medical University, Ceramiczna 1, 20-150 Lublin, Poland, Tel: +48 81 718 73 65, Fax: +48 81 718 73 64
 
J Pre Clin Clin Res. 2014;8(2):76–80
KEYWORDS
ABSTRACT
The aim of the present study was to characterize the anticonvulsant effects of levetiracetam in combination with ethosuximide in the mouse 6 Hz psychomotor seizure model. Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32 mA, 6 Hz, 3 s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10. With type II isobolographic analysis, the combinations of levetiracetam with ethosuximide for the fixed-ratios of 1:5 and 1:10 were supra-additive (synergistic; P<0.05 and P<0.01, respectively) in terms of seizure suppression, while the combinations for the fixed-ratios of 1:1 and 1:2 were additive in the mouse 6 Hz psychomotor seizure model. The combinations of levetiracetam with ethosuximide for the fixed-ratios of 1:5 and 1:10 appear to be particularly favorable combinations exerting supra-additive interaction in the mouse 6 Hz psychomotor seizure model. Finally, it may be concluded that because of the synergistic interactions between levetiracetam and ethosuximide, the combination might be useful in clinical practice.
 
REFERENCES (25)
1.
Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006; 66: 1817.
 
2.
Deckers CLP, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364.
 
3.
Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand. 1995; Suppl.162: 31.
 
4.
Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002; 11: 349.
 
5.
Łuszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004; 45: 895.
 
6.
EP 2 462 990 A1. European Patent Application https://data.epo.org/ publication-server/rest/v1.0/publication-dates/20120613/patents/ EP2462990NWA1/document.pdf (access: 2014.01.13).
 
7.
Wojda E, et al. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res. 2009; 86: 163.
 
8.
Florek-Łuszczki M, Wlaź A, Łuszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model – A type II isobolographic analysis. Eur J Pharmacol. 2014; 723: 410.
 
9.
Łuszczki JJ, et al. Additive interaction of levetiracetam with lamotrigine in the mouse 6 Hz psychomotor seizure model – an isobolographic analysis. Curr Issues Pharm Med Sci. 2013; 26: 82.
 
10.
Łuszczki JJ, et al. Isobolographic characterization of interaction of levetiracetam with clobazam in the mouse 6 Hz psychomotor seizure model. J Pre-Clin Clin Res. 2012; 6: 25.
 
11.
Barton ME, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001; 47: 217.
 
12.
Dudra-Jastrzebska M, et al. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure 2009; 18: 607–614.
 
13.
Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99–113.
 
14.
Tallarida RJ. Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton, 2000.
 
15.
Porreca F, Jiang Q, Tallarida RJ. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol. 1990; 179: 463–468.
 
16.
Łuszczki JJ, et al. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch Pharmacol. 2006; 373: 169–181.
 
17.
Gąsior M, et al. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm. 1996; 103: 819–831.
 
18.
Madeja M, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661–671.
 
19.
Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18.
 
20.
Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306: 5–8.
 
21.
Rigo JM, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002; 136: 659–652.
 
22.
Palma E, et al. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) “phasic” receptors. Proc Natl Acad Sci USA. 2007; 104: 20944.
 
23.
Lynch BA, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101: 9861–9866.
 
24.
Brodie MJ, Schachter SC. Fast Facts. Epilepsy. 2nd ed. Oxford, Health Press, 2001.
 
25.
Crunelli V, Leresche N. Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr. 2002; 2: 53–56.
 
eISSN:1898-7516
ISSN:1898-2395